Pretreatment with different doses of oliceridine attenuates etomidate-induced myoclonus during painless gastroscopy:...

Etomidate is commonly used for sedation during gastroscopy but is associated with a high incidence of myoclonus. This study evaluated the effectiveness of oliceridine pretreatment in reducing etomidate-induced myoclonus.

In this prospective, double-blind, randomized controlled trial, 150 patients undergoing painless gastroscopy were assigned to receive oliceridine at 0.01 mg/kg (Group A₁), 0.02 mg/kg (Group A₂), or normal saline (Group S) prior to etomidate administration. Remifentanil (0.2 μg/kg) and etomidate (0.3 mg/kg) were then administered. The incidence and severity of myoclonus were assessed within 60 s post-etomidate injection. Hemodynamic parameters, adverse effects, and satisfaction scores were also evaluated.

The incidence of myoclonus was significantly lower in Groups A₁ (28%) and A₂ (16%) compared to Group S (58%) (p < 0.001). Severe myoclonus occurred less frequently in the oliceridine groups. Heart rate (HR) at T₁ and T₂ was significantly lower in Groups A₁ and A₂ than in Group S (p < 0.05). No significant intergroup differences were observed in mean arterial pressure (MAP) or pulse oxygen saturation (SpO₂). Injection pain, hiccups, and cough were less frequent in the oliceridine groups, although not statistically significant.

Pretreatment with oliceridine effectively reduces the incidence and severity of etomidate-induced myoclonus during painless gastroscopy without compromising hemodynamic stability.

http://www.chictr.org.cn, identifier ChiCTR2500103005.